Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. [electronic resource]
Producer: 20130107Description: 2007-17 p. digitalISSN:- 1474-547X
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Analysis of Variance
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents -- administration & dosage
- Azetidines -- administration & dosage
- Cholesterol, HDL -- blood
- Cholesterol, LDL -- blood
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Therapy, Combination
- Ezetimibe
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors -- administration & dosage
- Hypercholesterolemia -- drug therapy
- Immunoglobulin G -- immunology
- Male
- Middle Aged
- Proprotein Convertase 9
- Proprotein Convertases -- antagonists & inhibitors
- Serine Endopeptidases -- immunology
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.